natgillin/translations-raw huggingface dataset:
If you experience prolonged bleeding when taking Iscover If you cut or injure yourself, it may take longer than usual for bleeding to stop.
Če doživite podaljšanje krvavitve v času jemanja zdravila Iscover Če se urežete ali poškodujete, lahko traja dlje kot običajno, da se vam krvavitev ustavi.
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see ‘Take special care with Iscover’).
Vendar pa se morate takoj posvetovati s svojim zdravnikom, če ste glede krvavitve v kakršnihkoli dvomih (glejte Bodite posebno pozorni pri jemanju zdravila Iscover).
Other side effects reported with Iscover are:
Drugi neželeni učinki, o katerih so poročali z zdravilom Iscover so:
HOW TO STORE ISCOVER
SHRANJEVANJE ZDRAVILA ISCOVER
Do not use Iscover after the expiry date which is stated on the carton and on the blister.
Ne uporabljajte zdravila Iscover po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu.
If Iscover is supplied in PVC/PVDC/aluminium blisters, store below 30°C.
Zdravilo Iscover, ki je na voljo v PVC/ PVDC/ alu pretisnih omotih shranjujte pri temperaturi do 30°C.
Do not use Iscover if you notice any visible sign of deterioration.
Ne uporabljajte zdravila Iscover, če ste opazili vidne znake kvarjenja.
40 Medicines should not be disposed of via wastewater or household waste.
41 Zdravila ne smete odvreči v odpadne vode ali med gospodinjske odpadke.
What Iscover contains The active substance is clopidogrel.
Kaj vsebuje zdravilo Iscover
Iscover 75-mg tablets are round, biconvex, pink, film-coated tablets engraved on one side with the number ‘75’ and on the other side with the number ‘1171’.
Iscover 75 mg tablete so okrogle, bikonveksne filmsko obložene tablete, rožnate barve, z vtisnjeno številko “ 75 ” na eni strani in številko “ 1171 ” na drugi strani.
They are supplied in cardboard cartons containing 7, 14, 28, 30, 84, 90 and 100 tablets in PVC/PVDC/Aluminium blisters or in all aluminium blisters, or 50x1 tablets in PVC/PVDC/Aluminium blisters or in all aluminium perforated unit-dose blisters.
Na voljo je v škatlah, ki vsebujejo 7, 14, 28, 30, 84, 90 in 100 tablet v PVC/ PVDC/ alu pretisnih omotih ali v pretisnih omotih iz aluminija, ali 50x1 tableta v PVC/ PVDC aluminijastih pretisnih omotih ali v aluminijastih perforiranih pretisnih omotih za enkratni odmerek.
България BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT.
България BRISTOL- MYERS SQUIBB
Magyarország BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT.
GYÓGYSZERKERESKEDELMI KFT.
43 PACKAGE LEAFLET:
43 Navodilo je bilo odobreno MM/ LLLL
INFORMATION FOR THE USER
44 NAVODILO ZA UPORABO
Iscover 300 -mg film-coated tablets clopidogrel
Iscover 300 mg filmsko obložene tablete klopidogrel
44 Take special care with Iscover:
možganih;
Iscover is not intended for use in children or adolescents.
Zdravilo Iscover ni namenjeno za uporabo pri otrocih ali mladostnikih.
You should specifically tell your doctor if you take a non-steroidal anti-inflammatory drug, usually used to treat painful and/or inflammatory conditions of muscle or joints, or if you take heparin or any other medicine used to reduce blood clotting.
Podrobno morate obvestiti svojega zdravnika, če jemljete nesteroidna protivnetna zdravila, ki se običajno uporabljajo za lajšanje bolečine in/ ali vnetja mišic ali sklepov, ali če jemljete heparin ali katerokoli drugo zdravilo, ki se uporablja za zmanjševanje strjevanja krvi.
45 Pregnancy and breast-feeding It is preferable not to use this product during pregnancy and breast-feeding.
Nosečnost in dojenje Priporočljivo je, da se tega zdravila v nosečnosti in med dojenjem ne uporablja.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Iscover.
46 Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta, preden vzamete zdravilo Iscover.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Iscover (1 tablet of 300 mg or 4 tablets of 75 mg) once at the start of treatment.
Če ste imeli hudo bolečino v prsih (nestabilna angina ali srčna kap), vam lahko zdravnik na začetku zdravljenja da enkrat 300 mg zdravila Iscover (eno 300- mg tableto ali štiri 75- mg tablete).
Then, the usual dose is one 75 mg tablet of Iscover per day to be taken orally with or without food, and at the same time each day.
Nato je običajni odmerek ena 75- mg tableta zdravila Iscover na dan, ki jo lahko vzamete s hrano ali brez nje; odmerek morate jemati vsak dan ob istem času.
Like all medicines, Iscover can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Iscover neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
not associated with bleeding which appears under the skin as red pinpoint dots, and/or confusion (see ‘Take special care with Iscover’).
s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ ali zmedenostjo (glejte Bodite posebno pozorni pri jemanju zdravila Iscover).
Bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma (unusual bleeding or
Krvavitve se lahko pojavijo kot krvavitve iz želodca ali črevesja, kot modrice, hematomi (neobičajne krvavitve ali modrice pod kožo), krvavitev iz nosu, kri v urinu.
If you experience prolonged bleeding when taking Iscover If you cut or injure yourself, it may take longer than usual for bleeding to stop.
47 Če doživite podaljšanje krvavitve v času jemanja zdravila Iscover Če se urežete ali poškodujete, lahko traja dlje kot običajno, da se vam krvavitev ustavi.
What Iscover looks like and contents of the pack
48 Izgled zdravila Iscover in vsebina pakiranja
They are supplied in cardboard cartons containing
Iscover 300 mg tablete so podolgovate, rožnate, filmsko obložene tablete, z vtisnjeno številko “ 300 ” na eni strani in številko “ 1332 ” na drugi strani.
47 4x1, 30x1 and 100x1 tablets in all aluminium perforated unit-dose blisters.
Na voljo je v škatlah, ki vsebujejo 4x1, 30x1, in 100x1 tableto v perforiranih pretisnih omotih za enkratni odmerek, ki so v celoti iz aluminija.
Bristol Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH United Kingdom
Sanofi Pharma Bristol- Myers Squibb SNC 174, Avenue de France, F - 75013 Paris – Francija
48 France BRISTOL-MYERS SQUIBB SARL Tél: + 33 (0)810 410 500
49 France BRISTOL- MYERS SQUIBB SARL Tél: + 33 (0) 810 410 500
Ísland VISTOR HF Sími: + 354 535 7000
Ísland VISTOR HF
It is available as pink, oval tablets (400 mg).
Na voljo je v obliki rožnatih ovalnih tablet (400 mg).
Isentress is an antiviral medicine.
Zdravilo Isentress je protivirusno zdravilo.
It is used in combination with other antiviral medicines to treat adults infected with human immunodeficiency virus (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Uporablja se v kombinaciji z drugimi protivirusnimi zdravili za zdravljenje odraslih, okuženih z virusom humane imunske pomanjkljivosti (HIV- 1), ki povzroča sindrom pridobljene imunske pomanjkljivosti (AIDS).
Isentress is only used in patients who are already being treated for their HIV infection, if tests show that the virus is multiplying in the blood despite treatment.
Zdravilo Isentress se uporablja le pri bolnikih, ki so se že zdravili zaradi okužbe z virusom HIV, če testi pokažejo, da se virus razmnožuje v krvi kljub zdravljenju.
Treatment with Isentress should be started by a doctor who has experience in the management of HIV infection.
Zdravljenje z zdravilom Isentress mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
It is given as one tablet twice a day, with or without food.
Zdravilo se daje v odmerku ene tablete dvakrat dnevno, skupaj s hrano ali brez nje.
Care should be taken when it is given to elderly patients or patients with severe liver problems.
Posebna pozornost je potrebna pri dajanju zdravila starejšim bolnikom ali bolnikom s hudimi jetrnimi težavami.
The active substance in Isentress, raltegravir, is an integrase inhibitor.
Raltegravir, zdravilna učinkovina zdravila Isentress, je zaviralec integraze.
It blocks an enzyme called integrase, which is involved in a step in the reproduction of HIV.
Učinkovina zavira encim, imenovan integraza, ki sodeluje v enem od korakov pri razmnoževanju virusa HIV.
When the enzyme is blocked, the virus cannot reproduce normally, slowing down the spread of infection.
Kadar je encim blokiran, se virus ne more razmnoževati tako kot običajno, kar zmanjša hitrost širjenja okužbe.
Isentress, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Zdravilo Isentress v kombinaciji z drugimi protivirusnimi zdravili zniža količino virusa HIV v krvi in jo ohranja na nizki ravni.
Isentress does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Zdravilo Isentress ne zdravi okužbe z virusom HIV ali AIDS- a, lahko pa podaljša čas do nastopa poškodb imunskega sistema in razvoja okužb ter bolezni, ki so povezane z AIDS- om.
The effects of Isentress were first tested in experimental models before being studied in humans.
Učinki zdravila Isentress so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The two main studies of Isentress, still ongoing and scheduled to last up to three years, have included a total of 699 HIV-infected patients.
Dve glavni študiji zdravila Isentress, ki še vedno potekata in naj bi trajali tri leta, vključujeta skupaj 699 bolnikov, okuženih z virusom HIV.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Vsi bolniki prejemajo „ optimizirano osnovno zdravljenje “ (kombinacijo drugih protivirusnih zdravil, izbranih za vsakega bolnika posebej, ki ponuja najboljše 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. možnosti za znižanje ravni virusa HIV v krvi), h kateremu se dodaja zdravilo Isentress ali placebo (zdravilo brez zdravilne učinkovine).
What benefit has Isentress shown during the studies?
Kakšne koristi je zdravilo Isentress izkazalo med raziskavami?
Isentress was more effective than placebo in reducing viral load.
Zdravilo Isentress je bilo pri zniževanju virusnega bremena bolj učinkovito kot placebo.
After 16 weeks, 77% of the patients who took Isentress in addition to optimised background therapy had viral loads below 400 copies per millilitre of blood, compared with 42% of the patients who received placebo plus optimised background therapy.
Po 16 tednih je imelo 77% bolnikov, ki so jemali zdravilo Isentress kot dodatek optimiziranemu osnovnemu zdravljenju, virusna bremena pod 400 kopij na mililiter krvi, v primerjavi z 42% bolnikov, ki so kot dodatek optimiziranemu osnovnemu zdravljenju jemali placebo.
The CHMP also considered the results seen after 24 and 48 weeks, which showed that the response seen at 16 weeks was sustained for at least 48 weeks.
Odbor CHMP je prav tako upošteval rezultate, zabeležene po 24 in 48 tednih zdravljenja, ki so pokazali, da so se odzivi, opaženi pri 16 tednih, ohranili najmanj 48 tednov.
The most common side effects with Isentress (seen in between 1 and 10 patients in 100) are insomnia (difficulty sleeping), dizziness, headache, abdominal distension (bloating), abdominal (tummy) pain, constipation, diarrhoea, flatulence (gas), nausea (feeling sick), vomiting, hyperhidrosis (excessive sweating), night sweats, pruritus (itching), rash, arthralgia (joint pain), asthenia (weakness), fatigue (tiredness) and increased blood levels of liver enzymes (alanine aminotransferase and aspartate aminotransferase), triglycerides (a type of fat), creatinine kinase (an enzyme found in muscles) and lipase (an enzyme found in the pancreas).
Najpogostejši neželeni učinki pri jemanju zdravila Isentress (opaženi pri 1 do 10 bolnikih izmed 100) so nespečnost, omotica, glavobol, napihnjenost trebuha, bolečine v trebuhu, zaprtje, driska, flatulenca (nabiranje plinov v želodcu ali črevesju), slabost, bruhanje, hiperhidroza (čezmerno potenje), nočno potenje, pruritus (srbenje), izpuščaj, artralgija (bolečine v sklepih), astenija (šibkost), utrujenost in povečane ravni jetrnih encimov (alanin aminotransferaze in aspartat aminotransferaze), trigliceridov (vrsta maščob), kreatinin kinaze (encim, ki se nahaja v mišicah) in lipaze (encim, ki se nahaja v trebušni slinavki) v krvi.
For the full list of all side effects reported with Isentress, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Isentress, glejte navodilo za uporabo.
Isentress should not be used in people who may be hypersensitive (allergic) to raltegravir or to any of the other ingredients.
Zdravila Isentress ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) raltegravir ali katero koli drugo sestavino zdravila.
As with other anti-HIV medicines, patients taking Isentress may be at risk of osteonecrosis (death of bone tissue) or immune reactivation syndrome (symptoms of infection caused by the recovering immune system).
Kot pri vseh drugih zdravilih proti virusu HIV obstaja tudi pri bolnikih, ki jemljejo zdravilo Isentress, tveganje za pojav osteonekroze (odmiranje kostnega tkiva) ali sindroma imunske reaktivacije (simptomi okužbe, ki se pojavijo zaradi okrevanja imunskega sistema).
During the studies, patients receiving Isentress developed more cancers than patients receiving optimised background therapy.
Med študijami se je pri bolnikih, ki so prejemali zdravilo Isentress, razvilo več rakastih obolenj kot pri bolnikih, ki so prejemali optimizirano osnovno zdravljenje.
It is not known if these cancers were due to Isentress.
Ni znano, ali so ta rakasta obolenja posledica jemanja zdravila Isentress.
The Committee for Medicinal Products for Human Use (CHMP) decided that Isentress’ s benefits, when taken in combination with other antiretroviral medicinal products, outweigh its risks for the treatment of HIV-1 infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Isentress, uporabljenega v kombinaciji z drugimi protivirusnimi zdravili, večje od z njim povezanih tveganj pri zdravljenju okužbe z virusom HIV- 1 pri odraslih bolnikih, ki so se že zdravili in pri katerih se kljub potekajočemu protivirusnemu zdravljenju virus HIV- 1 razmnožuje dalje.
This indication is based on 48-week data from two studies comparing it with placebo.
Indikacija temelji na 48 - tedenskih podatkih dveh študij, v katerih so zdravilo primerjali s placebom.
The Committee recommended that Isentress be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Isentress odobri dovoljenje za promet.
Isentress has been given ‘ Conditional Approval’.
Zdravilo Isentress je bilo „ pogojna odobreno “.
This means that there is more evidence to come about the medicine.
To pomeni, da se v zvezi z zdravilom pričakujejo dodatni dokazi.
Every year, the European Medicines Agency (EMEA) will review any new information that may become available, and this summary will be updated as necessary.
Evropska agencija za zdravila (EMEA) bo vsako leto pregledala morebitne nove razpoložljive informacije in po potrebi posodobila ta povzetek.
What information is still awaited for Isentress?
Katere informacije o zdravilu Isentress še pričakujemo?
The company that makes Isentress will set up studies to monitor the development of resistance to raltegravir.
Družba, ki proizvaja zdravilo Isentress bo pripravila študije za spremljanje razvoja odpornosti na raltegravir.
The European Commission granted a marketing authorisation valid throughout the European Union for Isentress to Merck Sharp & Dohme Limited on 20 December 2007.
Evropska komisija je dovoljenje za promet z zdravilom Isentress, veljavno po vsej Evropski uniji, odobrila družbi Merck Sharp & Dohme Limited dne 20. decembra 2007.
The full EPAR for Isentress can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Isentress je na voljo tukaj.
EU Number EU/ 1/ 07/ 436/ 001 EU/ 1/ 07/ 436/ 002
Številka EU EU/ 1/ 07/ 436/ 001 EU/ 1/ 07/ 436/ 002
Invented name ISENTRESS ISENTRESS
Izmišljeno ime ISENTRESS ISENTRESS
Strength 400 mg 400 mg
jakost 400 mg 400 mg
Pharmaceutical Form Film-coated tablets Film-coated tablets
farmacevtska oblika Filmsko obložene tablete Filmsko obložene tablete
Route of Administration Oral use Oral use
pot uporabe Peroralna uporaba Peroralna uporaba
Packaging Bottle (HDPE) Bottle (HDPE)
ovojnina Plastenka (HDPE) Plastenka (HDPE)
Package size 60 tablets 180 (3x60) tablets
velikost pakiranja 60 tablet 180 (3x60) tablet
Each tablet contains 26.06 mg lactose monohydrate.
Ena tableta vsebuje 26, 06 mg laktoze monohidrata.
Pink, oval tablet, marked with "227" on one side.
Rožnata, ovalna tableta, z oznako "227" na eni strani.
ISENTRESS is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing anti-retroviral therapy.
Zdravilo ISENTRESS je v kombinaciji z drugimi protiretrovirusnimi zdravili indicirano za zdravljenje okužbe z virusom humane imunske pomanjkljivosti (HIV- 1) pri že zdravljenih odraslih bolnikih z dokazom razmnoževanja virusa HIV- 1 kljub potekajočemu protiretrovirusnemu zdravljenju.
This indication is based on safety and efficacy data from two double-blind, placebo-controlled trials of 48 weeks duration in treatment-experienced patients (see section 5.1).
Indikacija temelji na podatkih o varnosti in učinkovitosti iz dveh dvojno slepih, s placebom nadzorovanih preskušanj pri že zdravljenjih bolnikih, ki sta trajali 48 tednov (glejte poglavje 5. 1).
ISENTRESS should be used in combination with other active anti-retroviral therapies (ARTs) (see sections 4.4 and 5.1).
Zdravilo ISENTRESS je treba uporabljati v kombinaciji z drugimi protiretrovirusnimi zdravili (glejte poglavji 4. 4 in 5. 1).
Posology Adults The recommended dosage of ISENTRESS is 400 mg administered twice daily with or without food.
Bolnik lahko zdravilo jemlje skupaj s hrano ali brez nje.
The effect of food on absorption of raltegravir is uncertain (see section 5.2).
Vpliv hrane na absorpcijo raltegravirja ni povsem znan (glejte poglavje 5. 2).
It is not recommended to chew, crush or split the tablets.
Tablet ni priporočljivo žvečiti, drobiti ali razpolavljati.
Elderly There is limited information regarding the use of ISENTRESS in the elderly (see section 5.2).
Starostniki Podatki o uporabi zdravila ISENTRESS pri starostnikih so omejeni (glejte poglavje 5. 2).
Therefore ISENTRESS should be used with caution in this population.
Pri tej starostni skupini bolnikov je treba zdravilo ISENTRESS uporabljati previdno.
Children and adolescents Safety and efficacy have not been established in patients below 16 years of age (see sections 5.1 and 5.2).
Otroci in mladostniki Pri bolnikih, mlajših od 16 let, varnosti in učinkovitosti niso dokazali (glejte poglavji 5. 1 in 5. 2).
Renal impairment No dosage adjustment is required for patients with renal impairment (see section 5.2).
Okvara ledvic Pri bolnikih z okvaro ledvic odmerka ni treba prilagajati (glejte poglavje 5. 2).
2 Hepatic impairment No dosage adjustment is required for patients with mild to moderate hepatic impairment.
2 Okvara jeter Pri bolnikih z blago do zmerno okvaro jeter odmerka ni treba prilagajati.
The safety and efficacy of ISENTRESS have not been established in patients with severe underlying liver disorders.
Pri bolnikih s hudo boleznijo jeter varnosti in učinkovitosti zdravila ISENTRESS niso dokazali.
Therefore ISENTRESS should be used with caution in patients with severe hepatic impairment (see sections 4.4 and 5.2).
Pri bolnikih s hudo okvaro jeter je treba zdravilo ISENTRESS uporabljati previdno (glejte poglavji 4. 4 in 5. 2).
Method of administration Oral
Način uporabe Peroralna uporaba.
Patients should be advised that current anti-retroviral therapy does not cure HIV and has not been proven to prevent the transmission of HIV to others through blood or sexual contact.
Bolnikom je treba pojasniti, da trenutne oblike protiretrovirusnega zdravljenja okužbe z virusom HIV ne pozdravijo, in da ni bilo dokazano, da bi lahko preprečile prenos virusa HIV na druge s krvjo ali pri spolnem odnosu.
Appropriate precautions should continue to be employed.
Bolniki morajo še vedno upoštevati ustrezne previdnostne ukrepe.
Overall, considerable inter- and intra-subject variability was observed in the pharmacokinetics of raltegravir (see sections 4.5 and 5.2).
Farmakokinetika raltegravirja se na splošno znatno razlikuje tako med različnimi osebami kot pri posamezni osebi (glejte poglavji 4. 5 in 5. 2).
Higher response rates were observed in patients with Genotypic Sensitivity Score (GSS) > 0.
Pri bolnikih z rezultatom genotipske občutljivosti (GSS; “ Genotypic Sensitivity Score ”), večjim od 0, je bil delež odziva na zdravljenje večji.
Patients with GSS or Phenotypic Sensitivity Score (PSS) = 0 had a higher risk of developing resistance to raltegravir (see section 5.1).
Pri bolnikih z rezultatom genotipske ali fenotipske občutljivosti (PSS; “ Phenotypic Sensitivity Score ”), enakim 0, obstaja večje tveganje za pojav odpornosti na raltegravir (glejte poglavje 5. 1).
Raltegravir should be used in combination with at least one other active agent to enhance benefit and to reduce the risk of virologic failure and development of resistance to raltegravir.
Za povečanje koristi in zmanjšanje tveganja za virološki neuspeh ter razvoj odpornosti na raltegravir je treba raltegravir uporabljati skupaj z vsaj še eno drugo zdravilno učinkovino.
Therefore ISENTRESS should be used with caution in patients with severe hepatic impairment (see sections 4.2 and 5.2).
Pri bolnikih s hudo okvaro jeter je treba zdravilo ISENTRESS uporabljati previdno (glejte poglavji 4. 2 in 5. 2).
Patients with pre-existing liver dysfunction including chronic hepatitis have an increased frequency of liver function abnormalities during combination anti-retroviral therapy and should be monitored according to standard practice.
Te bolnike je treba spremljati v skladu z običajno prakso.
There are very limited data on the use of raltegravir in patients co-infected with HIV and hepatitis B virus (HBV) or hepatitis C virus (HCV).
Podatki o uporabi raltegravirja pri bolnikih, sočasno okuženih z virusom HIV in virusom hepatitisa B (HBV) ali virusom hepatitisa C (HCV), so zelo omejeni.
Patients with chronic hepatitis B or C and treated with combination anti-retroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.
Pri bolnikih s kroničnim hepatitisom B ali kroničnim hepatitisom C, ki se zdravijo s kombiniranim protiretrovirusnim zdravljenjem, obstaja večje tveganje za pojav resnih in potencialno smrtnih neželenih učinkov na jetra.
Osteonecrosis Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/ or long-term exposure to combination anti-retroviral therapy.
Osteonekroza Čeprav so vzroki za osteonekrozo različni (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo in višjim indeksom telesne mase), so o primerih osteonekroze poročali še posebej pri bolnikih z napredovalo okužbo z boleznijo HIV in/ ali pri dolgotrajnem kombiniranem protiretrovirusnem zdravljenju.